Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Likely Flaws Uncovered for LM-Method for Lyme Disease Detection

By LabMedica International staff writers
Posted on 12 Jul 2016
According to a new study, the recently developed modified microscopy technique “LM-method” of examining blood samples to help diagnose Lyme disease (and babesiosis) – is unable to distinguish infected patients from healthy controls, yielding many false-positive results.

While most people who contract Lyme disease recover quickly after antibiotic treatment, up to 20% of patients report persistent symptoms years after being told standard tests are negative for the disease. Interest in new diagnostic tests is therefore high.

The tick vector Ixodidae transmits Borrelia (bacterial causative agent of Lyme disease) as well as Babesia (parasitic protozoan causative agent of babesiosis). The new research follows up on a previous study suggesting that LM-method could detect active cases of disease caused by Borrelia and/or Babesia in just 1-2 days. Considerable publicity, and thereby patient demand, for this test in Norway continued despite that earlier studies did not include a control group and methods were not validated and ready for use in patients.

To investigate the reliability of the new test, Dr Audun Aase, from the Norwegian Institute of Public Health (Oslo, Norway), and colleagues collected blood samples from people who had been suffering from Lyme disease-like symptoms for several years and previously tested positive for Borrelia and/or Babesia infection using LM-method (21 people), and from healthy controls with no known history of tick bites (41 people). The samples were then masked and analyzed in independent laboratories using a range of diagnostic tests including the LM-method, conventional microscopy, genetic fingerprint testing (PCR), and serology.

The study indicated that LM-method results in high numbers of false positives: 14 (66%) patient-group samples and 35 (85%) control-group samples were judged positive for Borrelia and/or Babesia. However, only 1 sample (5%) of the patient-group and 8 samples (20%) of the control-group tested positive for Borrelia DNA by PCR. None of the samples were positive for Babesia DNA, and conventional microscopy did not identify Babesia in any of the samples. In conclusion, the structures interpreted as Borrelia and Babesia using LM-method could not be verified by PCR and the LM-method was thus falsified.

In an accompanying editorial commentary, Dr Ram B. Dessau, infectious diseases expert and senior consultant at Slagelse Hospital (Slagelse, Denmark), wrote: “I hope the study serves as a warning against non-validated microscopic procedures and helps prevent mismanagement of patients with chronic complaints, who are lured to seek improper diagnosis in the future.”

The study, by Aase A et al, was published online February 2016 in the journal Infectious Diseases.

Related Links:
Norwegian Institute of Public Health



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.